Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).

CONCLUSION: Febuxostat had stronger renoprotective and antioxidant effects than topiroxostat in patients with hyperuricemia and CKD.
PMID: 31748427 [PubMed - as supplied by publisher]

Source: Annals of Thoracic and Cardiovascular Surgery - November 20, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Sezai A, Unosawa S, Taoka M, Osaka S, Sekino H, Tanaka M Tags: Ann Thorac Cardiovasc Surg Source Type: research